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Protein misfolding is the primary cause
of several systemic and neurodegenera-
tive diseases[1,2] and a major challenge in
the development of protein-based thera-
peutics,[3] Figure 1 top. In misfolding dis-
eases such as cystic fibrosis and a1-anti-
trypsin deficiency, degradation and/or
mistrafficking of specific proteins causes
loss of protein function. A second class
of misfolding disease includes systemic
amyloidoses, type II diabetes, Alzheimer’s
disease, and Parkinson’s disease. These
are caused by gains of toxic function re-
sulting from the aggregation of specific
misfolded proteins into highly ordered
structures, termed amyloid fibrils,
Figure 1. Amyloid-like protein aggregates
that act as infectious agents by replicat-
ing and transmitting their misfolded
state are called prions,[4] Figure 1. Prion
diseases include Creuzfeldt–Jakob dis-
ease (CJD), Gertsmann–Straussler syn-
drome (GSS), and fatal familial insomnia
(FFI) in humans, bovine spongiform en-
cephalopathy (BSE) in cattle, scrapie in
sheep, and chronic wasting disease in
elk. These diseases are characterized by
the presence of an abnormal form of the
prion protein (PrP) in the brain.[5] Prion
aggregates isolated from tissues or pre-
pared in vitro from purified recombinant
proteins share a common core structure
(cross-b-sheet), have fibrillar morpholo-
gies, and show dye-binding properties
that are akin to classical amyloids. The
transmission of prion diseases through
misfolded and/or aggregated form(s) of
the prion protein as an infectious agent
distinguishes them from other amyloid
diseases.
Given their link to disease, research in-
terest in amyloids and prions has been
centered on understanding the molecu-
lar mechanisms that govern their forma-
tion and toxicity.[2] The goal is to identify
molecules or agents that can inhibit
and/or reverse these processes in vitro
and disease progression in animal
models. During the last decade, the
debate on amyloids has shifted from
whether they are the cause or conse-
quence of disease[6] to whether they
might even have a protective physiologi-
cal role. The idea of amyloids as being a
protective rather than a toxic species is
anchored in the recognition that amyloid
formation appears to be a property that
is generic to many proteins. Further-
more, amyloid fibrils and prions appear
to be essential constituents of many
living organisms and are associated with
a number of important biological func-
tions.[1, 7] In bacterial cells, the process of
amyloid formation has been linked to
biofilm formation on their surfaces.[8] In
mammalian cells, amyloid formation me-
diates melanin formation,[9] synaptic
changes involved in memory storage,[10]
and trait inheritance.[11]
Figure 1. Schematic illustration of the proposed mechanisms of protein misfolding, prion formation,
and prion propagation in yeast. The molecular chaperone Hsp104 plays a critical role in prion propaga-
tion by fragmenting prion particles, thereby creating additional seeds that nucleate the formation of
additional prion particles, which are transmitted through the daughter cells.
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Generating Inventories of
Functional Amyloids
The full extent to which amyloid forma-
tion is used in biological functions re-
mains unknown. Clearly, this knowledge
will be useful for understanding the
mechanisms by which cells process or
utilize pathological amyloid formation. It
also has relevance for understanding the
role of amyloid formation in the regula-
tion of different biological processes. To
fill these gaps in our knowledge, it is
useful to start with an inventory of puta-
tive amyloid-forming sequences. Annota-
tions of these sequences will provide
hints regarding the functional/dysfunc-
tional roles of amyloid formation. The
availability of fully sequenced genomes
provides a useful starting point for iden-
tifying putative amyloid-forming sequen-
ces through genome-wide scans. With
an inventory in hand, one can assess the
amyloid-forming potential and the func-
tional consequences of amyloid forma-
tion for each sequence.
Recent Progress
Although the approach outlined above
is easy to articulate in theory, there are
numerous hurdles to overcome, not the
least of which is the lack of clarity re-
garding the signatures of amyloid-form-
ing sequences. The recent work of Lind-
quist and co-workers[12] provides the first
proof-of-concept study that starts with
genome-wide scanning to generate an
inventory of putative amyloid formers
(yeast prions in this case) and then goes
beyond this inventory to identify the
bona fide prions. Starting with prior
knowledge regarding the signatures of
prion-forming domains in Sup35, Ure2p,
and Rnq1, Alberti et al. trained a hidden
Markov model and carried out a pro-
teome-wide scan of the S. cerevisiae
genome.[12] The scan yielded about 200
putative proteins with prion-forming do-
mains. The training set biased the search
to identify proteins with lengthy do-
mains that are rich in either glutamine
and/or asparagine residues. Based on
these sequence characteristics, they
identified 200 candidate proteins con-
taining prion-coding sequences, which
were tested by using an array of func-
tional in vivo assays and in vitro biophys-
ical studies. Alberti et al. selected the top
100 candidate proteins from their scan
to determine if they possess prion-like
properties. Specifically, they tested the
ability of these proteins to 1) form cyto-
solic foci, 2) form ordered aggregates
that are resistant to detergent, 3) form
amyloids in vitro as monitored by using
thioflavin-T (ThT) fluorescence, 4) gen-
erate so-called [PSI+] states by using
ACHTUNGTRENNUNGchimeras of candidate prion-forming do-
mains with the N- and C-terminal do-
mains of Sup35.[12]
Not all Primary Amides are
the Same
Prior to this study, it was believed that,
although the glutamine and asparagine
content is important in determining the
prion-forming propensity of a given
ACHTUNGTRENNUNGsequence, the actual ratio of glutamine
to asparagine plays a minor role. The
ACHTUNGTRENNUNGassessments of Alberti et al. yielded a
rather surprising result, because they no-
ticed that the aggregation-prone prion-
forming domains tended to be enriched
in asparagine residues. Conversely, the
false-positive putative prions were en-
riched in glutamine residues as well as
prolines and charged residues Figure 2.
One might argue that this result is the
consequence of enrichment in charged
residues and amyloid breakers such as
proline. Lindquist and co-workers have
initiated studies to understand the pref-
erence for asparagine-rich—as opposed
to glutamine-rich—regions in strongly
amyloidogenic prion-forming sequences.
Understanding the Origins of
the Observed Specificities
Polyglutamine-rich regions have occu-
pied the attention of researchers in the
amyloid field because of their association
with nine neurodegenerative diseas-
es.[13,14] In these diseases, there is a strik-
ing inverse correlation between the
lengths of polyglutamine expansions
within specific proteins and the ages-of-
onset for diseases associated with the
aggregation of these proteins or their
fragments.[15] Biophysical studies have
shed light on several important aspects
of polyglutamine tracts.[16–21] In aqueous
milieus, monomeric polyglutamine forms
collapsed structures to minimize the in-
terface with the milieu.[17,22] In short poly-
glutamine tracts, this preference for col-
lapsed structures can be reversed by the
addition of multiple lysine residues at
the N and C termini.[23] Initial studies
suggested that polyglutamine aggrega-
tion proceeds through a homogeneous
nucleation mechanism involving the for-
mation of a monomeric, b-sheet confor-
mation.[24] Recent investigations indicate
that the mechanism of polyglutamine
aggregation is considerably more com-
plex and in all likelihood involves the
spontaneous formation of either spheri-
cal aggregates[21] or large linear aggre-
gates[20] depending on the presence or
absence of flanking lysine residues. The
formation of ordered aggregates—which
might be questionable for polyglutamine
alone—appears to be a slow step that
involves conformational rearrangements
of small numbers of molecules within
droplets that can be referred to as
molten oligomers.[25,26] Polyglutamine
molecules collapse on themselves partly
because the side-chain primary amides
solvate backbone secondary amides;
similarly, soluble molten oligomers form
primarily through favorable interactions
between side-chain primary amides.
If the preference for asparagine-rich
regions in putative prion-forming do-
mains originates in intrinsic differences
between asparagine and glutamine resi-
dues, then it should be possible to tease
out these differences by comparing the
conformational ensembles for monomer-
ic and oligomeric polyglutamine and
polyasparagine, respectively. Alternative-
ly, the differences observed by Alberti
et al. might reflect the effects of different
sequence contexts, which modulate the
common intrinsic preferences of aspara-
gine and glutamine residues (Figure 2).
Ongoing studies from different laborato-
ries that utilize combinations of tech-
niques will allow us to dissect the origin
for the observed specificity for aspara-
gine over glutamine in putative prion-
forming domains. Of particular interest is
the role of sequence context and coarse-
grain characteristics such as the charge/
hydropathy of flanking sequences in de-
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termining the differential prion-/amyloid-
forming abilities of glutamine- and as-
paragine-rich regions.
Looking Ahead
The ability of proteins to adopt function-
al and pathogenic states sharing similar
structural properties suggests that for-
mation of the functional state is tightly
regulated and occurs under defined con-
ditions. It has been hypothesized that
proteins do not have to choose between
an amyloidogenic/prionogenic and a
functional state; rather, they can switch
back and forth between the two states
in response to cellular cues and/or envi-
ronmental stresses. This hypothesis is
supported by increasing evidence dem-
onstrating the dynamic nature and rever-
sibility of amyloid formation.[27,28] If this
is true, then what determines whether
an amyloid or prionogenic protein is
pathogenic or beneficial? Solving this
puzzle requires detailed analysis of the
prion-coding domains; we also need a
mapping of proteins’ intracellular locali-
zation and their roles in different biologi-
cal pathways. The ability of proteins to
form distinct fibrillar morphologies from
the same precursor protein, that is, prion
strains, also remains a mystery.[29] This
concept has important implications for
the diversity in function and pathogenic-
ity of amyloid- and prion-forming pro-
teins and might constitute the molecular
basis underlying the ability of these pro-
teins to switch between the different
states.
The work of Alberti et al. is encourag-
ing and constitutes an important first
step toward more large-scale studies de-
signed to answer precise questions re-
garding the amyloid-forming abilities of
different sequences, not just those that
contain glutamine- and asparagine-rich
regions. In particular, systematic studies
are needed to assess the validity of vari-
ous predictors of amyloidogenicity that
have been developed by different labo-
ratories.[30–32] Such studies will provide us
with an improved understanding of
comparative driving forces and mecha-
nisms of protein aggregation and are
likely to be useful in developing quanti-
tative models that enable us to under-
stand how cells process deleterious or
functional aggregates. From a biological
standpoint, the work of Alberti et al. is
encouraging because it is suggestive of
routes that can be explored to discover
novel amyloid- and prion-forming candi-
dates in the genomes of other organ-
isms, especially those exposed to stress-
ful environments where the ability to
switch between different functional con-
formations might be advantageous. A
better understanding of the sequence
determinants of amyloid and prion for-
mation and propagation and the molec-
ular determinants that govern the rever-
sibility between functional and patho-
Figure 2. Schematic illustration of the primary sequence of the prionogenic glutamine- and/or asparagine-rich domains of the prion proteins Ure2p (Swiss-
Prot P23202), Sup35NM (Swiss-Prot P05453), Rnq1p (Swiss-Prot P25367), HET-s (Swiss-Prot B8M2I5) and three of the prion candidates identified by Alberti
et al. MOT3 (Swiss-Prot P54785), NRP1 (Swiss-Prot P32770), and SWI1 (Swiss-Prot P09547). Glutamine residues are shown in red and asparagine residues are in
blue.
ChemBioChem 2009, 10, 1951 – 1954  2009 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chembiochem.org 1953
Sequence Determinants of Prion Formation
genic amyloids and prions will improve
our understanding of how nature main-
tains the delicate balance between the
two states to generate novel biological
functions and protect against disease.
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